RT Book, Section
A1 Stannard, Karen M.
A1 Dlugos, Dennis J.
A1 Glauser, Tracy
A2 Sirven, Joseph I.
A2 Stern, John M.
SR Print(0)
ID 1103049241
T1 Absence Seizures
T2 Atlas of Video-EEG Monitoring
YR 2011
FD 2011
PB McGraw-Hill Education
PP New York, NY
SN 9780071597425
LK neurology.mhmedical.com/content.aspx?aid=1103049241
RD 2024/04/19
AB First  described  over  200  years  ago  by  Tissot,  childhood  absence  epilepsy  (CAE)  is  a  common  pediatric  epilepsy  syndrome  that  affects  otherwise  normal  children,  with  onset  between  ages  4  and  10  years  and  with  a  peak  onset  between  6  and  7  years.1–5  Commonly  misperceived  as  a  “benign”  epilepsy  syndrome,  patients  with  CAE  demonstrate  variable  response  to  therapy,  exhibit  cognitive  deficits,  encounter  elevated  rates  of  accidental  injury,  demonstrate  long-term  psychosocial  difficulties,  and  have  variable  remission  rates.  Similar  to  other  epilepsies,  the  current  therapeutic  approach  for  children  with  CAE  is  empiric:  an  antiepileptic  drug  (AED)  is  selected  based  on  available  data  and  clinical  experience,  then  titrated  to  an  acceptable  balance  of  seizure  control  and  side  effects.